Clinuvel Pharmaceuticals (CUV) is enhancing its vitiligo treatment pipeline by integrating the proprietary Vitiligo Visual Algorithm (VVA), an AI tool for objective clinical image assessment. Showcased at AAD 2026 in Denver, the VVA tracks treatment progress using standardized photographs, currently utilized in the CUV105 study and planned for the upcoming CUV107 Phase III trial. The company is gathering feedback from dermatologists during the conference. Clinuvel also highlighted its melanocortin therapies, including afamelanotide, FDA-approved for erythropoietic protoporphyria (EPP), which has EMA endorsement for year-round treatment in Europe. Financially, Clinuvel reported A$36.9 million in revenue for H1 2026 but saw a 26% drop in profit due to increased operational costs. Despite this, they maintain a strong financial position with no debt and cash reserves of A$233 million. The company is focused on advancing vitiligo studies and plans to broaden its U.S. investor base with a Nasdaq application.
Source link
